2016年
1. Yoshio S, Sugiyama M, Shoji H, Mano Y, Mita E, Okamoto T, Matsuura Y, Okuno A, Takikawa O, Mizokami M and Kanto T. Indoleamine-2, 3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. Hepatology. 63(1):83-94. 2016. 1 
2. Ueyama M, Nishida N, Korenaga M, Korenaga K, Kumagai E, Yanai H, Adachi H, Katsuyama H, Moriyama S, Hamasaki H, Sako A, Sugiyama M, Aoki Y, Imamura M, Murata K, Masaki N, Kawaguchi T, Torimura T, Hyogo H, Aikata H, Ito K, Sumida Y, Kanazawa A, Watada H, Okamoto K, Honda K, Kon K, Kanto T, Mizokami. The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. J Gastroenterol. 51(4):370-9. 2016. 4
3. Kumagai E, Korenaga K, Korenaga K, Imamura M, Ueyama M, Aoki Y, Sugiyama M, Murata K, Masaki N, Kanto T, Mizokami M, Watanabe S. Appropriate Use of Virtual Touch Quantification and FibroScan® M and XL Probes According to the Skin Capsular Distance. J Gastroenterol. 51(5):496-505. 2016.5
4. Yoshio S, Kanto T. Host-virus interactions in hepatitis B and hepatitis C infection. J Gastroenterol. 51(5):409-20. 2016.5
5. Shoji H, Yoshio S, Mano Y, Kumagai E, Sugiyama M, Korenaga M, Arai T, Itokawa N, Atsukawa M, Aikata H, Hyogo H,,Chayama K, Ohashi T, Ito K, Yoneda M, Nozaki Y, Kawaguchi T, Torimura T, Abe M, Hiasa Y, Fukai M, Kamiyama T, Taketomi A, Mizokami M, Kanto T. Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Scientific Reports, 2016 Jul 1;6:28814.
6. Sugiyama M, Kanto T. Dual blockade of hepatitis C virus entry at a gatekeeper of hepatocytes: Not only a preventive, but also therapeutic target of claudin 1. Hepatology. 2016 Sep;64(3):979-82.
7. Kumagai E, Mano Y, Yoshio S, Shoji H, Sugiyama M, Korenaga M, Ishida T, Arai T, Itokawa N, Atsukawa M, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Kawaguchi T, Torimura T, Nozaki Y, Watanabe S, Mizokami M, Kanto T. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep. 2016 Oct 14;6:35282.
和文
- 大座紀子, 考藤達哉. 治療の経費と肝炎治療特別促進事業. B型、C型肝炎の抗ウイルス療法：最前線の治療エッセンス 医薬ジャーナル社, 2016
- 考藤達哉. B型肝炎ワクチンの現状と課題. The Japanese Juornal of Antibiotics69: 1190-120, 2016.
共著論文
1. Nagata N, Kawazoe A, Mishima S, Wada T, Shimbo T, Sekine K, Watanabe K, Imbe K, Kojima Y, Kumazawa K, Mihara F, Tokuhara M, Edamoto Y, Igari T, Yanase M, Mizokami M, Akiyama J, Uemura N. Development of Pancreatic Cancer, Disease-specific Mortality, and All-Cause Mortality in Patients with Nonresected IPMNs: A Long-term Cohort Study. Radiology,278,(1), 125-34, 2016.1
2. Dansako H, Ueda Y, Okumura N, Satoh S, Sugiyama M, Mizokami M, Ikeda M, Kato N. The cyclic GMP-AMP synthetase-STING signaling pathway is required for both the innate immune response against HBV and the suppression of HBV assembly. FEBS J. 283(1):144-56. 2016. 1
3. Iio E, Ocho M, Togayachi A, Nojima M, Kuno A, Ikehara Y, Hasegawa I, Yatsuhashi H, Yamasaki K, Shimada N, Ide T, Shinkai N, Nojiri S, Fujiwara K, Joh T, Mizokami M, Narimatsu H, Tanaka Y. A novel glycobiomarker, Wisteria floribunda agglutinin macrophage colony-stimulating factor receptor, for predicting carcinogenesis of liver cirrhosis. Int J Cancer. 15;138(6):1462-71. 2016. 3
4. Abe SK, Inoue M, Sawada N, Iwasaki M, Shimazu T, Yamaji T, Sasazuki S, Saito E, Tanaka Y, Mizokami M, Tsugane S. Hepatitis B and C virus infection and risk of pancreatic cancer: A population-based cohort study (JPHC Study Cohort II). Cancer Epidemiol Biomarkers Prev. 25(3):555-7. 2016. 3
5. Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, Zhu Y, Knox SJ, Pang P, Subramanian M, Kowdley K, Afdhal NH. Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older. Hepatology. 63(4):1112-9. 2016.4
6. Tokushige K, Hyogo H, Nakajima T, Ono M, Kawaguchi T, Honda K, Eguchi Y, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Suzuki Y, Kogiso T, Karino Y, Munekage K, Kuromatsu R, Oeda S, Yanase M, Mori K, Ogawa Y, Seko Y, Takehara T, Itoh Y, Nakajima A, Kanemasa K, Nishino K, Masaki N, Takahashi H, Seike M, Torimura T, Saibara T, Toyota J, Chayama K, Hashimoto E. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. J Gastroenterol. 51(6):586-96. 2016.6
7. Nishida N, Ohashi J, Khor SS, Sugiyama M, Tsuchiura T, Sawai H, Hino K, Honda M, Kaneko S, Yatsuhashi H, Yokosuka O, Koike K, Kurosaki M, Izumi N, Korenaga M, Kang JH, Tanaka E, Taketomi A, Eguchi Y, Sakamoto N, Yamamoto K, Tamori A, Sakaida I, Hige S, Itoh Y, Mochida S, Mita E, Takikawa Y, Ide T, Hiasa Y, Kojima H, Yamamoto K, Nakamura M, Saji H, Sasazuki T, Kanto T, Tokunaga K, Mizokami M. Understanding of HLA-conferred susceptibility to chronic hepatitis B infection requires HLA genotyping-based association analysis. Scientific Reports, 2016 Apr 19;6:24767.
8. Yamagiwa Y, Asano M, Kawasaki Y, Korenaga M, Murata K, Kanto T, Mizokami M, Masaki N. Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy. Cytokine 88 (2016) 29-36
9. Nishitsuji H, Ujino S, Yoshio S, Sugiyama M, Mizokami M, Kanto T, Shimotohno K. Long noncoding RNA #32 contributes to antiviral responses by controlling interferon-stimulated gene expression. Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10388-93.
